A federal judge in California has granted final approval to Gilead Sciences’ settlement of $247 million with direct purchasers of HIV medications. This conclusion comes as a resolution to accusations towards the bio-pharmaceutical company of collaboration with Teva Pharmaceuticals in order to delay the release of generic alternatives of these drugs. The settlement, which includes an impressive sum of $75 million intended for attorney fees, puts an end to these claims.
This case has highlighted the ongoing tension in the pharmaceutical arena, where corporate giants like Gilead Sciences are often alleged to employ tactics aiming to delay generic competition. These practices carry significant ramifications as they directly affect the pricing and accessibility of life-saving drugs, making it a major concern for both professionals and consumers within the medical and health sectors.
For more detailed information on this case, you can read the report on
Law360.